These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34343275)

  • 1. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort.
    De Matteis A; Bracaglia C; Pires Marafon D; Piscitelli AL; Alessio M; Naddei R; Orlando F; Filocamo G; Minoia F; Ravelli A; Tibaldi J; Cimaz R; Marino A; Simonini G; Mastrolia MV; La Torre F; Tricarico I; Licciardi F; Montin D; Maggio MC; Alizzi C; Martini G; Civino A; Gallizzi R; Olivieri AN; Ardenti Morini F; Conti G; De Benedetti F; Pardeo M
    Rheumatology (Oxford); 2022 Apr; 61(4):1621-1629. PubMed ID: 34343275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
    Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
    Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
    Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
    N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
    Grom AA; Ilowite NT; Pascual V; Brunner HI; Martini A; Lovell D; Ruperto N; ; Leon K; Lheritier K; Abrams K
    Arthritis Rheumatol; 2016 Jan; 68(1):218-28. PubMed ID: 26314396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
    Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
    Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
    Kostik MM; Isupova EA; Belozerov K; Likhacheva TS; Suspitsin EN; Raupov R; Masalova VV; Chikova IA; Dubko MF; Kalashnikova OV; Chasnyk VG; Cron RQ
    Front Pediatr; 2022; 10():894846. PubMed ID: 35967555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
    Ulu K; Aliyev E; Kılıç Könte E; Tanatar A; Türkmen Ş; Doğantan Ş; Kızıldağ Z; Kasap Demir B; Gezgin Yıldırım D; Otar Yener G; Öztürk K; Baba Ö; Açarı C; Kılbaş G; Taşkın SN; Haşlak F; Çağlayan Ş; Bağlan E; Dundar HA; Başaran Ö; Barut K; Karadağ ŞG; Coşkuner T; Sönmez HE; Yüksel S; Kalyoncu M; Bakkaloğlu SA; Ünsal E; Paç Kısaarslan A; Bilginer Y; Aktay Ayaz N; Kasapçopur Ö; Özen S; Sözeri B
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI167-SI172. PubMed ID: 38441301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
    Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
    J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Orrock JE; Ilowite NT
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K; Hara R; Umebayashi H; Takei S; Iwata N; Imagawa T; Shimizu M; Tomiita M; Seko N; Kitawaki T; Yokota S
    Mod Rheumatol; 2021 Jan; 31(1):226-234. PubMed ID: 32552266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
    Iwata N; Nishimura K; Hara R; Imagawa T; Shimizu M; Tomiita M; Umebayashi H; Takei S; Seko N; Wakabayashi R; Yokota S
    Mod Rheumatol; 2023 Nov; 33(6):1162-1170. PubMed ID: 36399020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
    Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.
    Coşkuner T; Çağlayan Ş; Akgün Ö; Torun R; Yayla ENS; Bagrul IL; Kılbaş G; Yener GO; Köse H; Öztürk K; Baba Ö; Çakan M; Demir F; Sönmez HE; Kalyoncu M; Kılıç SS; Yüksel S; Bağlan E; Bakkaloğlu SA; Ünsal E; Aktay Ayaz N; Sözeri B
    Expert Opin Biol Ther; 2023; 23(12):1299-1306. PubMed ID: 37970654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
    Alexeeva E; Krekhova E; Dvoryakovskaya T; Isaeva K; Chomakhidze A; Chistyakova E; Lomakina O; Denisova R; Mamutova A; Fetisova A; Gautier M; Vankova D; Kriulin I; Saygitov R
    Front Pediatr; 2023; 11():1114207. PubMed ID: 36911042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Toplak N; Blazina Š; Avčin T
    Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.